Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

US Judge Upholds Validity Of Merck's Vytorin Patent

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2012 | 12:03am CET
   By Peter Loftus 
   Of  
 

A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (>> Merck & Co., Inc.) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years.

In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable.

Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017.

Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable.

Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday.

On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said.

A Mylan spokeswoman couldn't immediately be reached.

Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million.

Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
02/26 MERCK : Letermovir, an Investigational Antiviral Medicine for Prevention of Cyto..
02/24 MERCK : In First Phase 3 Trial, Merck’s Investigational Inactivated Varice..
02/24 MERCK : Study Findings from Merck & Company Broaden Understanding of Hepatitis C..
02/24 RECENT STUDIES FROM MERCK & COMPANY : A...
02/24 MERCK : Announces EPOCH Study of Verubecestat for the Treatment of People with M..
02/24 MERCK : New Data from Merck & Company Illuminate Findings in Immunoglobulins (Tr..
02/24 MERCK : Study Results from Merck & Company in the Area of Vaccines Reported (Des..
02/24 MERCK : Research Data from Merck & Company Update Understanding of Hypertension ..
02/24 DATA FROM MERCK & COMPANY ADVANCE KN : a snapshot of recent data in pediatric an..
02/24 MERCK : Researchers at Merck & Company Report New Data on Melanoma (Population P..
More news
Sector news : Pharmaceuticals - NEC
08:35aDJASTRAZENECA : FDA OKs Once-Daily Qtern for Type-2 Diabetes
02/27DJJOHNSON & JOHNSON : Prescription Unit List Prices Rose 8.5% Last Year
02/27 FTSE ends higher on some positive earnings, insurers slip
02/27DJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
02/24DJSHIRE : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/27 Idera Pharmaceuticals' Well-Funded And Growing Pipeline Of Potentially Blockb..
02/27 Roche's Renal Success Spells Danger For All-Comer Studies
02/26 BIOTECH FORUM DAILY DIGEST : Can Aerie Pharmaceuticals Continue To Rally? Spotli..
02/24 Merck's VZV vaccine candidate successful in first late-stage study in immunoc..
02/24 SYNERGY : 3 Scenarios, 1 Choice
Advertisement
Financials ($)
Sales 2017 39 712 M
EBIT 2017 13 517 M
Net income 2017 8 459 M
Debt 2017 4 774 M
Yield 2017 2,85%
P/E ratio 2017 20,14
P/E ratio 2018 17,11
EV / Sales 2017 4,69x
EV / Sales 2018 4,54x
Capitalization 181 558 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 68,7 $
Spread / Average Target 4,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.12.38%181 558
JOHNSON & JOHNSON6.53%332 993
ROCHE HOLDING LTD.5.42%209 283
PFIZER INC.5.48%204 030
NOVARTIS AG4.72%203 039
SANOFI4.59%110 124
More Results